Jungeun Song1, So Won Kim, Hyun Ju Hong, Min Goo Lee, Byoung Wook Lee, Tai Kiu Choi, Sang-Hyuk Lee, Ki-Hwan Yook. 1. *Department of Psychiatry, National Health Insurance Service, Ilsan Hospital, Goyang; †Suicide and School Mental Health Research Center, Anyang; ‡Department of Clinical pharmacology, Busan Paik Hospital, Busan; §Department of Neuropsychiatry, College of Medicine, Hallym University, Anyang; ║Department of Pharmacology, Pharmacogenomic Research Center for Membrane Transporters, Brain Korea 21 PLUS Project for Medical Science, College of Medicine, Yonsei University, Seoul; and ¶Department of Psychiatry, Bundang CHA Medical Center, School of Medicine, CHA University, Seongnam, Republic of Korea.
Abstract
OBJECTIVES: Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS: One hundred thirty-nine children and adolescents with attention-deficit/hyperactivity disorder (ADHD) were recruited. We selected rs192303, rs3785143 in SLC6A2; rs3746544 (1065 T>G) in SNAP-25; and rs6551665, rs1947274, and rs2345039 in LPHN3 to examine the association of OROS MPH treatment response with each single nucleotide polymorphism. We first defined good response group when the Korean version of the ADHD rating scale score at 8 weeks was decreased for more than 50% of baseline scores and compared genotype frequencies in good response group with poor group. Second, we defined it when the Clinical Global Impression-Improvement score at 8 weeks was 1 or 2, and we also analyzed the genotype frequencies. RESULTS: There was a significant association between the 1065 T>G of SNAP-25 gene and OROS MPH response, with the good response group defined by the Korean version of ADHD rating scale scores; 33.3% of the subjects with GG genotype showed a good response, whereas 74.7% of those with TT genotype and 72.5% of those with TG genotype showed good responses (P=0.034). SLC6A2 rs192303 was related with OROS MPH treatment response when we defined good treatment response by Clinical Global Impression-Improvement (P=0.009). CONCLUSIONS: Our study suggested that SNAP-25 gene and SLC6A2 were involved with OROS MPH response.
OBJECTIVES: Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS: One hundred thirty-nine children and adolescents with attention-deficit/hyperactivity disorder (ADHD) were recruited. We selected rs192303, rs3785143 in SLC6A2; rs3746544 (1065 T>G) in SNAP-25; and rs6551665, rs1947274, and rs2345039 in LPHN3 to examine the association of OROS MPH treatment response with each single nucleotide polymorphism. We first defined good response group when the Korean version of the ADHD rating scale score at 8 weeks was decreased for more than 50% of baseline scores and compared genotype frequencies in good response group with poor group. Second, we defined it when the Clinical Global Impression-Improvement score at 8 weeks was 1 or 2, and we also analyzed the genotype frequencies. RESULTS: There was a significant association between the 1065 T>G of SNAP-25 gene and OROS MPH response, with the good response group defined by the Korean version of ADHD rating scale scores; 33.3% of the subjects with GG genotype showed a good response, whereas 74.7% of those with TT genotype and 72.5% of those with TG genotype showed good responses (P=0.034). SLC6A2rs192303 was related with OROS MPH treatment response when we defined good treatment response by Clinical Global Impression-Improvement (P=0.009). CONCLUSIONS: Our study suggested that SNAP-25 gene and SLC6A2 were involved with OROS MPH response.
Authors: B S da Silva; R B Cupertino; D L Rovaris; J B Schuch; D B Kappel; D Müller; C E Bandeira; M M Victor; R G Karam; N R Mota; L A Rohde; V Contini; E H Grevet; C H D Bau Journal: Mol Psychiatry Date: 2017-05-02 Impact factor: 15.992
Authors: Ariel F Martinez; Yu Abe; Sungkook Hong; Kevin Molyneux; David Yarnell; Heiko Löhr; Wolfgang Driever; Maria T Acosta; Mauricio Arcos-Burgos; Maximilian Muenke Journal: Biol Psychiatry Date: 2016-07-14 Impact factor: 13.382
Authors: Mauricio Arcos-Burgos; Jorge I Vélez; Ariel F Martinez; Marta Ribasés; Josep A Ramos-Quiroga; Cristina Sánchez-Mora; Vanesa Richarte; Carlos Roncero; Bru Cormand; Noelia Fernández-Castillo; Miguel Casas; Francisco Lopera; David A Pineda; Juan D Palacio; Johan E Acosta-López; Martha L Cervantes-Henriquez; Manuel G Sánchez-Rojas; Pedro J Puentes-Rozo; Brooke S G Molina; Margaret T Boden; Deeann Wallis; Brett Lidbury; Saul Newman; Simon Easteal; James Swanson; Hardip Patel; Nora Volkow; Maria T Acosta; Francisco X Castellanos; Jose de Leon; Claudio A Mastronardi; Maximilian Muenke Journal: Transl Psychiatry Date: 2019-01-29 Impact factor: 6.222
Authors: Pedro J Puentes-Rozo; Johan E Acosta-López; Martha L Cervantes-Henríquez; Martha L Martínez-Banfi; Elsy Mejia-Segura; Manuel Sánchez-Rojas; Marco E Anaya-Romero; Antonio Acosta-Hoyos; Guisselle A García-Llinás; Claudio A Mastronardi; David A Pineda; F Xavier Castellanos; Mauricio Arcos-Burgos; Jorge I Vélez Journal: Cells Date: 2019-08-16 Impact factor: 6.600